Clinical Trial Protocol
Iranian Registry of Clinical Trials

05 Jul 2026

Comparison of the efficacy and adverse effects of visipaque and Ultravist in Contrast-enhanced CT Scan

Protocol summary

Summary

120 patients referred for evaluation of abdomen by contrast-enhanced CT Scan were included in this study. Patients were randomly allocated into two groups, group A and group B. Exclusion criteria: severe fatty liver; diabetes, hepatic tumor and portal vein thrombosis. Each group received a different contrast agent through IV route. Group A received 150 cc iodixanol (visipaque)300mgI/ml and group B received 150 cc iopromide(Ultravist300mgI/ml). CT scan were obtained with Somatom helical CT scanner (Simense, Germany). The contrast agents were injected via a power injector via antecubital vein using a gauge 18 needle. Images were obtained 60 second after injection. Injection pressure after each injection was recorded. Hepatic, portal and aortal enhancements were determined 60 second after injection. Adverse effects in 1 hour after injection and up to 1 week after injection were recorded using two questionnaires.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138904144316N1**
Registration date: **2011-01-08, 1389/10/18**
Registration timing: **retrospective**

Last update:
Update count: **0**

Registration date

2011-01-08, 1389/10/18

Registrant information

Name

Farideh Gharekhanloo

Name of organization / entity

Hamedan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 81 1264 0064

Email address

f_gharekhanloo@umsha.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Hamedan University of Medical sciences

Expected recruitment start date

2009-09-23, 1388/07/01

Expected recruitment end date

2010-05-22, 1389/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the efficacy and adverse effects of visipaque and Ultravist in Contrast-enhanced CT Scan

Public title

Comparison of the efficacy and adverse effects of visipaque and Ultravist in Contrast-enhanced CT Scan

Purpose

Diagnostic

Inclusion/Exclusion criteria

Inclusion criteria : patients reffered for abdomenoplevic CT Exclusion criteria : renal disease, Diabetes, known drug reaction

Age

No age limit

Gender

Both

Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: **120**
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Hamedan University of Medical sciences Ethics Committee
Street address
Besat Hospital
City
Hamedan
Postal code
6514845411
Approval date
2010-03-09, 1388/12/18
Ethics committee reference number
253/3/54/16/p

Health conditions studied

1

Description of health condition studied
All of patients referred to abdominal and pelvic CT
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Increasing of contrast enhancement
Timepoint
60 seconds after injection
Method of measurement
dansitometry with CTscan appratus

Secondary outcomes

1

Description
complication post injection
Timepoint
To one week after injection
Method of measurement
registrationin questionare

Intervention groups

1

Description
injection contrast ultravist 300mgI/ml
Category
Diagnosis

2

Description
injection contrast of visi paque300mgI/ml
Category
Diagnosis

Recruitment centers

1

Recruitment center
Name of recruitment center
Department of Radiology, Besat Hospital
Full name of responsible person
Dr Farideh Gharekhanloo
Street address
Besat hospital
City
Hamedan

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Vice chancellor for research, Hamedan University of Medical Sciences
Full name of responsible person
Dr Ghaleiha
Street address
Besat hospital
City
Hamedan
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source

Vice chancellor for research, Hamedan University of Medical Sciences

Proportion provided by this source
100

Public or private sector
empty

Domestic or foreign origin
empty

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
Hamedan University of Medical sciences

Full name of responsible person
Dr Farideh Gharekhanloo

Position
Academic member

Other areas of specialty/work

Street address
Besat hospital

City
Hamedan

Postal code
6514845411

Phone
+98 81 1264 0064

Fax
+98 81 1264 0064

Email
f_gharekhanloo@umsha.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Hamedan University of Medical sciences

Full name of responsible person
Dr Farideh Gharekhanloo

Position
Academic member

Other areas of specialty/work

Street address
Besat hospital

City
Hamedan

Postal code
6514845411

Phone
+98 81 1264 0064

Fax
+98 81 1264 0064

Email
f_gharekhanloo@umsha.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity
Hamedan University of Medical sciences

Full name of responsible person
Dr Farideh Gharekhanloo

Position
Academic member

Other areas of specialty/work

Street address
Besat hospital

City
Hamedan

Postal code
6514845411

Phone
+98 81 1264 0064

Fax
+98 81 1264 0064

Email
f_gharekhanloo@umsha.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty

Study Protocol
empty

Statistical Analysis Plan
empty

Informed Consent Form
empty

Clinical Study Report
empty

Analytic Code
empty

Data Dictionary
empty